Subtopic Deep Dive
IL-6 JAK STAT3 Signaling
Research Guide
What is IL-6 JAK STAT3 Signaling?
IL-6 JAK STAT3 signaling is the pathway where interleukin-6 (IL-6) binds the soluble IL-6 receptor (sIL-6R) and gp130, activating JAK1/2 kinases to phosphorylate STAT3 at Y705, driving transcription of acute phase and inflammatory genes.
IL-6 trans-signaling via sIL-6R/gp130 recruits JAK1 and JAK2, leading to STAT3 dimerization and nuclear translocation (Heinrich et al., 2003, 3199 citations). Dysregulation promotes cancer and autoimmunity through persistent STAT3 activation (Yu et al., 2009, 4220 citations). Over 10,000 papers cite core mechanisms since 1998.
Why It Matters
IL-6 JAK STAT3 signaling drives acute phase responses in infections and chronic inflammation in rheumatoid arthritis and cancers (Tanaka et al., 2014, 4677 citations). STAT3 hyperactivation supports tumor progression and immune evasion, positioning it as a therapeutic target with JAK inhibitors like tofacitinib (Johnson et al., 2018, 2942 citations). Pathway convergence with MAPK enables combined blockade in cytokine storms and solid tumors (Zhao et al., 2021, 2441 citations).
Key Research Challenges
Therapeutic Resistance Mechanisms
STAT3 reactivation via feedback loops limits JAK inhibitor efficacy in cancers (Johnson et al., 2018). Compensatory MAPK crosstalk sustains signaling despite IL-6 blockade (Zhang and Liu, 2002). Clinical trials show variable responses due to gp130 polymorphisms (Yu et al., 2014).
Pathway Crosstalk Complexity
IL-6 JAK STAT3 integrates with IFN and MAPK pathways, complicating selective inhibition (Platanias, 2005). Heinrich et al. (2003) detail gp130-mediated convergence amplifying inflammation. Quantifying interaction strengths remains unresolved (Hu et al., 2021).
Trans-Signaling Specificity
Distinguishing classic vs. trans-signaling via sIL-6R drives tissue-specific pathology (Tanaka et al., 2014). Mutations in gp130 alter STAT3 phosphorylation kinetics (Heinrich et al., 1998). Biomarker development for patient stratification lags (Yu et al., 2009).
Essential Papers
IL-6 in Inflammation, Immunity, and Disease
Toshio Tanaka, Masashi Narazaki, T Kishimoto · 2014 · Cold Spring Harbor Perspectives in Biology · 4.7K citations
Interleukin 6 (IL-6), promptly and transiently produced in response to infections and tissue injuries, contributes to host defense through the stimulation of acute phase responses, hematopoiesis, a...
STATs in cancer inflammation and immunity: a leading role for STAT3
Hua Yu, Drew M. Pardoll, Richard Jove · 2009 · Nature reviews. Cancer · 4.2K citations
Mechanisms of type-I- and type-II-interferon-mediated signalling
Leonidas C. Platanias · 2005 · Nature reviews. Immunology · 3.4K citations
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
Peter C. Heinrich, Iris Behrmann, Serge Haan et al. · 2003 · Biochemical Journal · 3.2K citations
The IL (interleukin)-6-type cytokines IL-6, IL-11, LIF (leukaemia inhibitory factor), OSM (oncostatin M), ciliary neurotrophic factor, cardiotrophin-1 and cardiotrophin-like cytokine are an importa...
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Daniel E. Johnson, Rachel A. O’Keefe, Jennifer R. Grandis · 2018 · Nature Reviews Clinical Oncology · 2.9K citations
MAPK signal pathways in the regulation of cell proliferation in mammalian cells
Wei Zhang, Hui-Tu Liu · 2002 · Cell Research · 2.8K citations
Inflammation and tumor progression: signaling pathways and targeted intervention
Huakan Zhao, Lei Wu, Guifang Yan et al. · 2021 · Signal Transduction and Targeted Therapy · 2.4K citations
Reading Guide
Foundational Papers
Start with Heinrich et al. (2003, 3199 citations) for IL-6-type cytokine principles via gp130/JAK/STAT; then Tanaka et al. (2014, 4677 citations) for inflammation context; Yu et al. (2009, 4220 citations) details STAT3 cancer roles.
Recent Advances
Johnson et al. (2018, 2942 citations) covers therapeutic targeting; Hu et al. (2021, 2165 citations) on JAK/STAT clinic translation; Zhao et al. (2021, 2441 citations) on inflammation-tumor links.
Core Methods
JAK inhibitors (tofacitinib); STAT3 phosphorylation assays (Y705 Western); gp130 dimerization FRET; RNA-seq for target genes; ODE modeling for dynamics (Heinrich et al., 1998; Zhang and Liu, 2002).
How PapersFlow Helps You Research IL-6 JAK STAT3 Signaling
Discover & Search
Research Agent uses searchPapers('IL-6 JAK STAT3 signaling cancer') to retrieve 250M+ OpenAlex papers, then citationGraph on Tanaka et al. (2014) maps 4677 citing works, and findSimilarPapers identifies pathway variants like Heinrich et al. (2003). exaSearch uncovers niche gp130 mutation studies.
Analyze & Verify
Analysis Agent applies readPaperContent to Johnson et al. (2018) for inhibitor response data, verifyResponse with CoVe cross-checks STAT3 Y705 claims against 10 papers, and runPythonAnalysis plots phosphorylation kinetics from extracted datasets with GRADE scoring for evidence strength.
Synthesize & Write
Synthesis Agent detects gaps in STAT3-MAPK crosstalk via contradiction flagging across Yu et al. (2009) and Zhang et al. (2002); Writing Agent uses latexEditText for pathway diagrams, latexSyncCitations for 20-paper bibliography, latexCompile for review manuscript, and exportMermaid for gp130-JAK-STAT3 flowcharts.
Use Cases
"Extract dose-response curves of JAK inhibitors on STAT3 phosphorylation from IL-6 stimulated cells"
Research Agent → searchPapers → Analysis Agent → readPaperContent (Johnson et al., 2018) → runPythonAnalysis (pandas curve fitting, matplotlib plots) → GRADE-verified IC50 table with statistical p-values.
"Draft a LaTeX review on IL-6 trans-signaling in oncology with citations"
Synthesis Agent → gap detection → Writing Agent → latexEditText (structure sections) → latexSyncCitations (Tanaka 2014, Yu 2009) → latexCompile → export pdf with embedded gp130 signaling Mermaid diagram.
"Find GitHub code for simulating IL-6 JAK STAT3 network dynamics"
Research Agent → paperExtractUrls (Heinrich et al., 2003) → paperFindGithubRepo → Code Discovery → githubRepoInspect → runPythonAnalysis (import sim code, NumPy ODE solver) → validated model outputs.
Automated Workflows
Deep Research workflow scans 50+ papers on IL-6 JAK STAT3 (searchPapers → citationGraph → DeepScan 7-steps with CoVe checkpoints) yielding structured report on therapeutic targets. Theorizer generates hypotheses on gp130 mutations from Heinrich et al. (1998/2003), simulating via runPythonAnalysis. DeepScan verifies MAPK crosstalk claims across Zhang et al. (2002) and Zhao et al. (2021).
Frequently Asked Questions
What defines IL-6 JAK STAT3 signaling?
IL-6 binds sIL-6R/gp130, activating JAK1/2 to phosphorylate STAT3 at Y705 for gene transcription (Heinrich et al., 2003).
What are key methods to study this pathway?
Western blots detect p-STAT3 Y705; ChIP-seq maps targets; CRISPR edits gp130 for signaling assays (Yu et al., 2009; Johnson et al., 2018).
What are the most cited papers?
Tanaka et al. (2014, 4677 citations) on IL-6 roles; Yu et al. (2009, 4220 citations) on STAT3 in cancer; Heinrich et al. (2003, 3199 citations) on principles.
What open problems exist?
Selective trans-signaling inhibitors; predicting resistance from pathway crosstalk; tissue-specific STAT3 isoforms (Johnson et al., 2018; Hu et al., 2021).
Research Cytokine Signaling Pathways and Interactions with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching IL-6 JAK STAT3 Signaling with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers